Regulation of angiogenesis and vascular permeability by src family kinases

Opportunities for therapeutic treatment of solid tumors

Serkin Park, Ami N. Shah, Jing Zhang, Gary E. Gallick

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.

Original languageEnglish
Pages (from-to)1207-1217
Number of pages11
JournalExpert Opinion on Therapeutic Targets
Volume11
Issue number9
DOIs
Publication statusPublished - 2007 Sep 1
Externally publishedYes

Fingerprint

src-Family Kinases
Capillary Permeability
Tumors
Neoplasms
Chemical activation
Therapeutics
Tumor Microenvironment
Deregulation
Endothelial cells
Protein-Tyrosine Kinases
Endothelial Cells
Clinical Trials
Neoplasm Metastasis
Molecules

Keywords

  • Angiogenesis
  • Metastasis
  • Protein tyrosine kinase
  • Src family kinase
  • Tumor progression
  • Tyrosine kinase inhibitors
  • Vascular permeability
  • VEGF

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Regulation of angiogenesis and vascular permeability by src family kinases : Opportunities for therapeutic treatment of solid tumors. / Park, Serkin; Shah, Ami N.; Zhang, Jing; Gallick, Gary E.

In: Expert Opinion on Therapeutic Targets, Vol. 11, No. 9, 01.09.2007, p. 1207-1217.

Research output: Contribution to journalReview article

@article{180dcd2de1c340fbaab15d784c685826,
title = "Regulation of angiogenesis and vascular permeability by src family kinases: Opportunities for therapeutic treatment of solid tumors",
abstract = "Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.",
keywords = "Angiogenesis, Metastasis, Protein tyrosine kinase, Src family kinase, Tumor progression, Tyrosine kinase inhibitors, Vascular permeability, VEGF",
author = "Serkin Park and Shah, {Ami N.} and Jing Zhang and Gallick, {Gary E.}",
year = "2007",
month = "9",
day = "1",
doi = "10.1517/14728222.11.9.1207",
language = "English",
volume = "11",
pages = "1207--1217",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "9",

}

TY - JOUR

T1 - Regulation of angiogenesis and vascular permeability by src family kinases

T2 - Opportunities for therapeutic treatment of solid tumors

AU - Park, Serkin

AU - Shah, Ami N.

AU - Zhang, Jing

AU - Gallick, Gary E.

PY - 2007/9/1

Y1 - 2007/9/1

N2 - Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.

AB - Aberrant expression or activation of protein tyrosine kinases, including Src and related Src family kinases, is a common occurrence in many human cancers, resulting in deregulation of expression of numerous mediators of cellular functions, including pro-angiogenic molecules. In addition, Src activation regulates vascular permeability of endothelial cells. How these processes contribute to tumor progression and metastasis are the subjects of this review. As Src-selective inhibitors have entered clinical trials for a number of solid tumors, further understanding of the roles of Src kinases in mediating tumor angiogenesis as well as modulating tumor/microenvironment interactions will provide insights into the best use of these inhibitors in treating patients afflicted with tumors in which Src is activated.

KW - Angiogenesis

KW - Metastasis

KW - Protein tyrosine kinase

KW - Src family kinase

KW - Tumor progression

KW - Tyrosine kinase inhibitors

KW - Vascular permeability

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=34548851971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548851971&partnerID=8YFLogxK

U2 - 10.1517/14728222.11.9.1207

DO - 10.1517/14728222.11.9.1207

M3 - Review article

VL - 11

SP - 1207

EP - 1217

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 9

ER -